PART I // Microbiome: new efficacy and toxicity endpoint in clinical study

Webinar presented by:

– SPEAKER: Françoise Le Vacon: Chief Scientific Officer

– MODERATOR: Stéphane Deniau: Business Manager

Exploring the microbiome: from sample to data analysis

Many nutritional or drug intervention strategies can modulate the microbiome. This topic about the microbiome will be splitted in 2 different webinars. In these 2 webinars, experts from Biofortis will cover steps from sample collection to data analysis in the microbiome assessment.
As a pioneer in Microbiome expertise, and an expert CRO, Biofortis designed and conducted more than 100 pre-clinical and clinical protocols integrating a microbiome component.

Part 1/ The microbiome : new efficacy and toxicity endpoint in clinical studies

In this first part of the “Exploring the microbiome” session, Françoise Le Vacon, CSO in Biofortis will describe the importance of analyzing the microbiome in clinical studies for the Food industry or for Drug development.

She will discuss:

– What about healthy or healthier microbiota?

– How to design a clinical study – from the volunteer side – with the regulatory aspect, inclusion/exclusion criteria, data collection, sampling etc.

– How to design a clinical study – from the microbiome side – with the sample prep, endpoints (Omic analysis, biochemical parameters), etc.

Françoise Le Vacon is Chief Scientific Officer and co-founder of Biofortis Mérieux NutriSciences.

As Microbiome Research Program Leader, Françoise has set up a platform for the study of bacterial ecosystems for clinical and pre-clinical applications in nutrition and health.

During this webinar, Stéphane Deniau, Business Manager in Biofortis, was the moderator of this session.

Webinar held on october, 6th 2020 at 5pm (CET).

Don’t hesitate to contact us, if you have any questions:

If you want to know more about clinical studies, you can watch an other webinar about Adaptives Design in Clinical trials.